WCWacothon-Karime Coulibaly

Wacothon-Karime Coulibaly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wacothon-Karime Coulibaly has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Corlu

    Université de Rennes 1, ImPACcell, SFR Biosit, Bât. 8, 2 Avenue du Professeur Léon Bernard, CS 34317, 35043 Rennes Cedex, France

    1 shared publication
  • Audrey Defontaine

    Station Biologique de Roscoff, USR 3151, CNRS-UPMC, Kinase Inhibitory Specialized Screening facility, KISSf, Place George Teissier, BP 74, 29682 Roscoff, France

    1 shared publication
  • Blandine Baratte

    Integrative Biology of Marine Models Laboratory (LBI2M), Sorbonne Université, CNRS, UMR 8227, Station Biologique de Roscoff, CS 90074, 29688 Roscoff Cedex, France

    1 shared publication
  • Camille Déliko Dago

    Université de Rennes 1, Institut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, Groupe ICMV, Bât. 10A, Campus de Beaulieu, 263 Avenue du Général Leclerc, CS 74205, 35042 Rennes Cedex, France

    1 shared publication
  • Christelle N´ta Ambeu

    Université de Rennes 1, Institut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, Groupe ICMV, Bât. 10A, Campus de Beaulieu, 263 Avenue du Général Leclerc, CS 74205, 35042 Rennes Cedex, France

    1 shared publication
  • J. A. Mamyrbekova-Bekro

    Laboratoire de Chimie Bio Organique et de Substances Naturelles (LCBOSN), Université Nangui Abrogoua (UNA), BP 802, Abidjan, Cote d’Ivoire

    1 shared publication

Latest Publications

  • Open Access

    Synthetic Development of New 3-(4-Arylmethylamino)butyl-5-arylidene-rhodanines under Microwave Irradiation and Their Effects on Tumor Cell Lines and against Protein Kinases

    by Camille Déliko Dago, Christelle N´ta Ambeu, Wacothon-Karime Coulibaly, Yves-Alain Békro, Janat Mamyrbékova, Audrey Defontaine, Blandine Baratte, Stéphane Bach, Sandrine Ruchaud, Rémy Le Guével, et al.

    A new route to 3-(4-arylmethylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-one 9 was developed in six steps from commercial 1,4-diaminobutane 1 as starting material. The key step of this multi-step synthesis involved a solution phase “one-pot two-steps” approach assisted by microwave dielectric from N-(arylmethyl)butane-1,4-diamine hydrochloride 6a–f (as source of the first point diversity) and commercial bis-(carboxymethyl)-trithiocarbonate reagent 7 for construction of the rhodanine platform. This platform was immediately functionalized by Knoevenagel condensation under microwave irradiation with a series of aromatic aldehydes 3 as second point of diversity. These new compounds were prepared in moderate to good yields and the fourteen synthetic products 9a–n have been obtained with a Z-geometry about their exocyclic double bond. These new 5-arylidene rhodanines derivatives 9a–n were tested for their kinase inhibitory potencies against four protein kinases: Human cyclin-dependent kinase 5-p25, HsCDK5-p25; porcine Glycogen Synthase Kinase-3, GSK-3α/β; porcine Casein Kinase 1, SsCK1 and human HsHaspin. They have also been evaluated for their in vitro inhibition of cell proliferation (HuH7 D12, Caco 2, MDA-MB 231, HCT 116, PC3, NCI-H727, HaCat and fibroblasts). Among of all these compounds, 9j presented selective micromolar inhibition activity on SsCK1 and 9i exhibited antitumor activities in the HuH7 D12, MDA-MBD231 cell lines.